Buy Ovagen Research Peptide

What is Ovagen?

Ovagen is a peptide bioregulator from the Russian research program, designed to target ovary and liver tissue. It is studied in animal research for its effects on reproductive-hormone and liver-tissue signaling in the context of aging.

• A short peptide studied for its effects on ovary and liver tissue
• Part of the Russian organ-targeted bioregulator research program
• Studied in animal research for its effects on reproductive-hormone signaling
• Investigated alongside Epithalon and Vesugen from the same program

For research use only. Not approved for human therapeutic use.

Ovagen is a synthetic tripeptide bioregulator with a molecular weight of 375.37 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Ovagen was designed based on peptide fractions associated with hepatic and ovarian tissue. As a tripeptide bioregulator, Ovagen falls between the dipeptide (Vilon, Thymagen, Vesilute) and tetrapeptide (Epithalon, Cortagen, Testagen) compounds within the Khavinson series. Like other bioregulators in this class, Ovagen is proposed to modulate tissue-specific gene expression through direct DNA interaction rather than conventional receptor-mediated signalling. Produced via solid-phase peptide synthesis, Ovagen is associated with hepatic and reproductive tissue gene expression pathways.

Ovagen is a tissue-specific tripeptide bioregulator within the Khavinson framework. Its proposed mode of is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1]. Ovagen is studied as a hepato-gastrointestinal-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [2]. The strongest EDL-specific in vivo evidence indexed to date is nephroprotective: in models of acute kidney injury, EDL administration was associated with preserved renal function, attenuation of oliguria and azotaemia, and maintenance of antioxidant defence [3], making Ovagen a reference compound in preclinical hepato-gastrointestinal research examining tissue-specific epithelial regeneration, age-associated decline in hepatic and intestinal protein synthesis, and organ-specific short-peptide regulation of gastrointestinal homeostasis.

Ovagen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 123749063Zamorskii II, Shchudrova TS, Lin’kova NS, Nichik TE, Khavinson VK. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bull Exp Biol Med. 2017 Jul 1;163(3):389–93. .PubMed PMID: 28744634

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Ovagen is a synthetic tripeptide bioregulator with a molecular weight of 375.37 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Ovagen was designed based on peptide fractions associated with hepatic and ovarian tissue. As a tripeptide bioregulator, Ovagen falls between the dipeptide (Vilon, Thymagen, Vesilute) and tetrapeptide (Epithalon, Cortagen, Testagen) compounds within the Khavinson series. Like other bioregulators in this class, Ovagen is proposed to modulate tissue-specific gene expression through direct DNA interaction rather than conventional receptor-mediated signalling. Produced via solid-phase peptide synthesis, Ovagen is associated with hepatic and reproductive tissue gene expression pathways.

Ovagen is a tissue-specific tripeptide bioregulator within the Khavinson framework. Its proposed mode of is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1]. Ovagen is studied as a hepato-gastrointestinal-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [2]. The strongest EDL-specific in vivo evidence indexed to date is nephroprotective: in models of acute kidney injury, EDL administration was associated with preserved renal function, attenuation of oliguria and azotaemia, and maintenance of antioxidant defence [3], making Ovagen a reference compound in preclinical hepato-gastrointestinal research examining tissue-specific epithelial regeneration, age-associated decline in hepatic and intestinal protein synthesis, and organ-specific short-peptide regulation of gastrointestinal homeostasis.

Ovagen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 123749063Zamorskii II, Shchudrova TS, Lin’kova NS, Nichik TE, Khavinson VK. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bull Exp Biol Med. 2017 Jul 1;163(3):389–93. .PubMed PMID: 28744634

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight379.37 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-OVAGEN-1504

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Ovagen is a synthetic tripeptide bioregulator with a molecular weight of 375.37 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Ovagen was designed based on peptide fractions associated with hepatic and ovarian tissue. As a tripeptide bioregulator, Ovagen falls between the dipeptide (Vilon, Thymagen, Vesilute) and tetrapeptide (Epithalon, Cortagen, Testagen) compounds within the Khavinson series. Like other bioregulators in this class, Ovagen is proposed to modulate tissue-specific gene expression through direct DNA interaction rather than conventional receptor-mediated signalling. Produced via solid-phase peptide synthesis, Ovagen is associated with hepatic and reproductive tissue gene expression pathways.

Ovagen is a tissue-specific tripeptide bioregulator within the Khavinson framework. Its proposed mode of is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1]. Ovagen is studied as a hepato-gastrointestinal-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [2]. The strongest EDL-specific in vivo evidence indexed to date is nephroprotective: in models of acute kidney injury, EDL administration was associated with preserved renal function, attenuation of oliguria and azotaemia, and maintenance of antioxidant defence [3], making Ovagen a reference compound in preclinical hepato-gastrointestinal research examining tissue-specific epithelial regeneration, age-associated decline in hepatic and intestinal protein synthesis, and organ-specific short-peptide regulation of gastrointestinal homeostasis.

Ovagen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 123749063Zamorskii II, Shchudrova TS, Lin’kova NS, Nichik TE, Khavinson VK. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bull Exp Biol Med. 2017 Jul 1;163(3):389–93. .PubMed PMID: 28744634

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight379.37 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-OVAGEN-1504

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.